Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961735 | 1.00 | GCK (0.34) | GCKALDH1A1LMNAMAPTMMP2 | |
| SCHEMBL1961732 | 1.00 | GCK (0.34) | GCKALDH1A1LMNAMAPTMMP2 | |
| SCHEMBL1963271 | 0.86 | GCK (0.42) | GCKALDH1A1LMNAMAPTCYP2C19 | |
| SCHEMBL1962960 | 0.82 | ALDH1A1 (0.35) | GCKALDH1A1LMNAMAPTCYP2C19 | |
| SCHEMBL1962959 | 0.82 | ALDH1A1 (0.35) | GCKALDH1A1LMNAMAPTCYP2C19 | |
| SCHEMBL1962958 | 0.82 | ALDH1A1 (0.35) | GCKALDH1A1LMNAMAPTCYP2C19 | |
| SCHEMBL1962618 | 0.81 | L3MBTL1 (0.34) | ALDH1A1LMNAMAPTMMP2POLB | |
| SCHEMBL1962623 | 0.81 | L3MBTL1 (0.34) | ALDH1A1LMNAMAPTMMP2POLB | |
| SCHEMBL1962620 | 0.81 | L3MBTL1 (0.34) | ALDH1A1LMNAMAPTMMP2POLB | |
| SCHEMBL1958901 | 0.81 | ALDH1A1 (0.35) | GCKALDH1A1LMNAMAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885ALDH1A1 769/4885LMNA 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.